Drug Trial Radar · NCT05917912
EASE (Efficacy of ATX01 Study in Erythromelalgia)
Last checked: Nov 19, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Jun 14, 2023
Primary completion
Feb 29, 2024
Study completion Feb 29, 2024
Sponsor
- Lead sponsor
- AlgoTherapeutixIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this two-center, randomized, double-blinded, parallel-group, placebo-controlled clinical study is designed to compare the efficacy of twice daily applications of ATX01 versus placebo during two consecutive 3-week treatment periods. The primary objective is the comparison between Treatments (ATX01 15% vs. Placebo) of mean pain attack intensity score assessed for the final week of each treatment period using an 11-point Numerical Pain Rating Scale (NPRS). Mean pain attack intensity is defined as the sum of the pain intensity score of each pain attack during the last 7 full days (Day 14 to Day 20) of each Treatment Period divided by the total number of erythromelalgia pain attacks during that 7-day period. Participants will apply on feet and/or hands twice a day in the morning and in the evening, approximately 12 hours apart from the morning administration for 3 consecutive weeks each and record the pain intensity of each attack that occurs.
Conditions
- Erythromelalgia
Interventions
Amitriptyline HydrochlorideDrug
hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
PlaceboDrug
hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison between Treatments (ATX01 15% vs. Placebo) of mean pain attack intensity scoreTime frame: during the last 7 full days (Day 14 to Day 20) of each Treatment Period
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Universitätsklinikum Erlangen Hautklinik
Erlangen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.